|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Asthma | |||||
| Lung Diseases | |||||
| 2 | More general conditions related to this trial | ||||
| Bronchial Diseases | |||||
| Hypersensitivity | |||||
| Hypersensitivity, Immediate | |||||
| Immune System Diseases | |||||
| Lung Diseases, Obstructive | |||||
| Respiratory Hypersensitivity | |||||
| Respiratory Tract Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| inhaled corticosteroids | |||||
| nedocromil | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anti-Allergic Agents | |||||
| Anti-Asthmatic Agents | |||||
| Anti-Inflammatory Agents | |||||
| Pharmacologic Actions | |||||
| Respiratory System Agents | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||